Menu
Search
|

Menu

Close
X

Alpine Immune Sciences Inc ALPN.OQ (NASDAQ Stock Exchange Global Market)

4.05 USD
-0.20 (-4.71%)
As of Jul 17
Previous Close 4.25
Open 4.15
Volume 1,313
3m Avg Volume 2,452
Today’s High 4.21
Today’s Low 4.05
52 Week High 8.61
52 Week Low 3.66
Shares Outstanding (mil) 18.57
Market Capitalization (mil) 76.14
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
1
FY17
2
FY16
3
EPS (USD)
FY19
-0.701
FY18
-2.634
FY17
-8.567
FY16
33.729
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.16
Price to Sales (TTM)
vs sector
195.24
8.16
Price to Book (MRQ)
vs sector
1.34
4.38
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
6.61
18.17
LT Debt to Equity (MRQ)
vs sector
2.96
13.01
Return on Investment (TTM)
vs sector
-64.05
12.64
Return on Equity (TTM)
vs sector
-66.78
17.19

EXECUTIVE LEADERSHIP

Mitchell Gold
Executive Chairman of the Board, Chief Executive Officer, Since 2017
Salary: $300,000.00
Bonus: --
Stanford Peng
President and Head of Research and Development, Since 2019
Salary: $375,000.00
Bonus: --
Paul Rickey
Chief Financial Officer, Senior Vice President, Since 2017
Salary: $206,250.00
Bonus: $50,000.00
Wayne Gombotz
Chief Technology Officer, Since 2019
Salary: --
Bonus: --
Min Cui
Director, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

201 Elliott Ave W Ste 230
SEATTLE   WA   98119-4230

Phone: +1206.7884545

Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.

SPONSORED STORIES